[go: up one dir, main page]

SG10201913485QA - Chimeric antigen receptors based on single-domain antibodies and methods of use thereof - Google Patents

Chimeric antigen receptors based on single-domain antibodies and methods of use thereof

Info

Publication number
SG10201913485QA
SG10201913485QA SG10201913485QA SG10201913485QA SG10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA
Authority
SG
Singapore
Prior art keywords
methods
chimeric antigen
domain antibodies
antigen receptors
receptors based
Prior art date
Application number
SG10201913485QA
Other languages
English (en)
Inventor
Xiaohu Fan
Chuan-Chu Chou
Qiuchuan Zhuang
Pingyan Wang
Lin Wang
Lei Yang
Jiaying Hao
Original Assignee
Legend Biotech Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legend Biotech Ireland Ltd filed Critical Legend Biotech Ireland Ltd
Publication of SG10201913485QA publication Critical patent/SG10201913485QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
SG10201913485QA 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof SG10201913485QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510490002 2015-08-11
CN201510733585.2A CN105384825B (zh) 2015-08-11 2015-11-02 一种基于单域抗体的双特异性嵌合抗原受体及其应用

Publications (1)

Publication Number Publication Date
SG10201913485QA true SG10201913485QA (en) 2020-02-27

Family

ID=55417644

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913485QA SG10201913485QA (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
SG11201900635QA SG11201900635QA (en) 2015-08-11 2017-08-10 Chimeric antigen receptors targeting bcma and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201900635QA SG11201900635QA (en) 2015-08-11 2017-08-10 Chimeric antigen receptors targeting bcma and methods of use thereof

Country Status (36)

Country Link
US (6) US10934363B2 (ko)
EP (7) EP4063397B1 (ko)
JP (8) JP6859347B2 (ko)
KR (7) KR20180035918A (ko)
CN (9) CN105384825B (ko)
AU (5) AU2016305075B2 (ko)
BR (1) BR112018002844A2 (ko)
CA (3) CA2994579C (ko)
CL (4) CL2018000378A1 (ko)
CO (2) CO2018001405A2 (ko)
CR (4) CR20210225A (ko)
DK (2) DK4063397T3 (ko)
EA (2) EA201890302A1 (ko)
ES (2) ES2984851T3 (ko)
FI (3) FI4063397T3 (ko)
FR (1) FR24C1050I1 (ko)
HR (2) HRP20241057T1 (ko)
HU (3) HUE067869T2 (ko)
IL (3) IL294683A (ko)
LT (2) LT4063397T (ko)
MX (5) MX2018001739A (ko)
MY (2) MY188362A (ko)
NL (1) NL301301I2 (ko)
NO (1) NO2024054I1 (ko)
NZ (2) NZ778787A (ko)
PH (2) PH12018500295B1 (ko)
PL (2) PL4063397T3 (ko)
PT (2) PT4063397T (ko)
RS (2) RS65866B1 (ko)
SA (2) SA518390904B1 (ko)
SG (2) SG10201913485QA (ko)
SI (2) SI4063397T1 (ko)
SM (2) SMT202400311T1 (ko)
UA (2) UA125818C2 (ko)
WO (2) WO2017025038A1 (ko)
ZA (2) ZA201800703B (ko)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CN104004095B (zh) * 2014-06-04 2016-11-23 博生吉医药科技(苏州)有限公司 一种cd7纳米抗体、其编码序列及应用
HUE070137T2 (hu) 2014-12-15 2025-05-28 Univ California CD19-re és CD20-ra érzékeny bispecifikus VAGY-kapu kiméra antigénreceptor
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
TW202444897A (zh) * 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP7190901B2 (ja) 2016-01-12 2022-12-16 クレッシェンド、バイオロジックス、リミテッド 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子
EP3416687A4 (en) 2016-02-17 2019-10-23 Seattle Genetics, Inc. BCMA ANTIBODIES AND USE THEREOF FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL ILLNESSES
CN110699371A (zh) * 2016-03-18 2020-01-17 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
AU2017240150C1 (en) 2016-04-01 2022-10-27 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof
SG11201808411RA (en) * 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
MX2018014228A (es) 2016-05-20 2019-08-12 Harpoon Therapeutics Inc Proteina de union de albumina sérica de dominio unico.
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
EP3474867A4 (en) * 2016-06-24 2020-05-20 iCell Gene Therapeutics LLC CHIMEAN ANTIGENT RECEPTORS (CARS) COMPOSITIONS AND METHODS FOR USE THEREOF
MX2019000641A (es) * 2016-07-15 2019-06-10 Poseida Therapeutics Inc Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
US11242386B2 (en) * 2016-07-18 2022-02-08 Helix Biopharma Corp. CEACAM6 CAR immune cells to treat cancers
KR102505681B1 (ko) 2016-09-14 2023-03-06 테네오바이오, 인코포레이티드 Cd3 결합 항체
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
CN106755109A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
CN106755108A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
BR112019011450A2 (pt) 2016-12-09 2019-10-15 Onkimmune Ltd células naturais killer modificadas e uso das mesmas
CN106822184A (zh) * 2016-12-15 2017-06-13 梁爱斌 多靶点联合的car‑t细胞制剂与制备方法
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN106749677B (zh) * 2017-01-04 2020-06-12 上海交通大学医学院附属瑞金医院 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
KR20190116420A (ko) 2017-02-17 2019-10-14 프레드 헛친슨 켄서 리서치 센터 Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
JP2020517287A (ja) 2017-04-26 2020-06-18 ユーリカ セラピューティックス， インコーポレイテッド キメラ抗体／ｔ細胞受容体構築物及びその使用
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
DK3618842T3 (da) 2017-05-01 2024-01-02 Juno Therapeutics Inc Kombination af en celleterapi og en immunomodulerende forbindelse
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
WO2018212770A1 (en) * 2017-05-17 2018-11-22 Thunder Biotech Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
CN107245500B (zh) * 2017-05-27 2019-05-17 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
CN107299110B (zh) 2017-05-27 2019-11-22 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
CN107337736B (zh) * 2017-06-06 2019-07-26 上海优卡迪生物医药科技有限公司 Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
IL312322A (en) * 2017-06-20 2024-06-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SG11201913175TA (en) * 2017-06-30 2020-01-30 The United States Of America As Represented By The Secretary Anti-b-cell maturation antigen chimeric antigen receptors with human domains
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN109232742B (zh) * 2017-07-11 2021-10-22 深圳市第二人民医院 一种嵌合抗原受体及其应用
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
CN109996872A (zh) * 2017-07-20 2019-07-09 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
US11976121B2 (en) * 2017-07-20 2024-05-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. CD123-binding chimeric antigen receptors
AU2018309735B2 (en) * 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
EP3675897A1 (en) * 2017-09-01 2020-07-08 Dana Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
WO2019055689A1 (en) * 2017-09-13 2019-03-21 Teneobio, Inc. HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES
CA3076972C (en) * 2017-09-29 2023-09-26 Mogam Institute For Biomedical Research Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
IL315737A (en) * 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP4435007A3 (en) * 2017-10-13 2024-12-25 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
AU2018360800B2 (en) 2017-11-01 2024-11-21 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
AU2018363291A1 (en) 2017-11-13 2020-05-21 Crescendo Biologics Limited Single domain antibodies that bind to CD137
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710040A1 (en) * 2017-11-15 2020-09-23 Novartis AG Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
CN111727373A (zh) 2017-11-30 2020-09-29 诺华股份有限公司 靶向bcma的嵌合抗原受体及其用途
CN111480345B (zh) 2017-12-14 2022-04-29 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
US20190192678A1 (en) * 2017-12-18 2019-06-27 Novather, Inc. System and method for the treatment of disease using a hyperspecific modified protein system
WO2019126724A1 (en) * 2017-12-22 2019-06-27 Bluebird Bio, Inc. Multivalent chimeric antigen receptor
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CN108285486A (zh) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
KR102115236B1 (ko) * 2018-01-29 2020-05-27 (주)에스엠티바이오 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
CN108341881B (zh) * 2018-01-31 2020-08-18 深圳市默赛尔生物医学科技发展有限公司 带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108314739B (zh) * 2018-02-05 2020-07-14 深圳市默赛尔生物医学科技发展有限公司 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN110129369B (zh) * 2018-02-09 2023-10-13 上海交通大学医学院附属上海儿童医学中心 一种嵌合抗原受体基因工程载体、免疫细胞及其应用
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
MX2020009116A (es) 2018-03-02 2020-12-07 Cdr Life Ag Proteinas triespecificas de union a antigenos.
CN108220247A (zh) * 2018-03-20 2018-06-29 杭州史迪姆生物科技有限公司 一种双car-t细胞及其制备方法和应用
AU2019249215A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
AU2019249221A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating glioblastomas
CN112218686A (zh) 2018-04-11 2021-01-12 印希比股份有限公司 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
CN110372796B (zh) * 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
MA52632A (fr) * 2018-05-16 2021-09-15 Janssen Biotech Inc Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
CN110606893B (zh) * 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
CN119529091A (zh) * 2018-06-19 2025-02-28 南京传奇生物科技有限公司 工程化的细胞及其用途
EP3823990A1 (en) * 2018-07-20 2021-05-26 TeneoBio, Inc. Heavy chain antibodies binding to cd19
EP3827019A1 (en) * 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US20210292389A1 (en) * 2018-08-10 2021-09-23 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
CA3110262C (en) 2018-08-24 2024-05-14 Shenzhen Pregene Biopharma Co. Ltd. Anti-bcma single domain antibodies and application thereof
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US20220364055A1 (en) 2018-08-31 2022-11-17 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3850013A4 (en) * 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND THEIR CONSTRUCTS
CN109293781A (zh) * 2018-09-12 2019-02-01 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
CN109081870B (zh) * 2018-09-21 2021-12-03 成都阿帕克生物科技有限公司 一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
JP2022501067A (ja) * 2018-09-26 2022-01-06 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
US12365728B2 (en) 2018-10-11 2025-07-22 Inhibrx Biosciences, Inc. DLL3 single domain antibodies and therapeutic compositions thereof
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
EP3870611A1 (en) * 2018-10-26 2021-09-01 TeneoBio, Inc. Heavy chain antibodies binding to cd38
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20210393689A1 (en) 2018-11-01 2021-12-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
CN109504660B (zh) * 2018-11-02 2021-08-06 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
JP2022512971A (ja) 2018-11-08 2022-02-07 ジュノー セラピューティクス インコーポレイテッド 処置およびｔ細胞調節のための方法および併用
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN110951689A (zh) * 2018-11-30 2020-04-03 北京美康基免生物科技有限公司 一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
US11793834B2 (en) * 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN109485732B (zh) * 2018-12-20 2021-09-24 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
CN113195542B (zh) * 2018-12-26 2024-05-24 南京传奇生物科技有限公司 Cd30-结合部分、嵌合抗原受体及其用途
CN109651511B (zh) * 2018-12-26 2020-06-09 广州百暨基因科技有限公司 一种靶向bcma的嵌合抗原受体及其应用
CN109652379B (zh) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020142815A1 (en) * 2019-01-07 2020-07-16 Celluris Participações Ltda Bispecific in tandem receptor car and method for modulating the tumoral microenvironment
CN109678961A (zh) * 2019-01-15 2019-04-26 深圳市南科生物工程有限公司 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
WO2020151752A1 (zh) * 2019-01-22 2020-07-30 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2020163325A1 (en) * 2019-02-04 2020-08-13 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途
KR20210134339A (ko) 2019-02-25 2021-11-09 노파르티스 아게 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
JP2022526595A (ja) 2019-04-05 2022-05-25 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2020261886A1 (en) * 2019-04-22 2021-11-18 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
JP7525510B2 (ja) 2019-05-04 2024-07-30 インヒブルクス インコーポレイテッド Ｃｄ３３結合性ポリペプチド及びその使用
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020247618A1 (en) * 2019-06-04 2020-12-10 The General Hospital Corporation Antibodies and chimeric antigen receptors that target taci
WO2020252366A1 (en) 2019-06-14 2020-12-17 Teneobio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CA3144871A1 (en) * 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
CN110540997B (zh) * 2019-08-29 2024-02-13 浙江煦顼技术有限公司 靶向bcma嵌合抗原受体、核酸序列、载体及应用
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
CA3152237A1 (en) * 2019-08-30 2021-03-04 Janssen Biotech, Inc. B-cell maturation complex car t construct and primers
WO2021043169A1 (zh) * 2019-09-02 2021-03-11 成都盛世君联生物技术有限公司 特异性结合b细胞成熟抗原的抗体及其用途
CN115151635A (zh) * 2019-09-18 2022-10-04 斯比根公司 用编码新的嵌合抗原受体的基因转导的基因修饰nk细胞系及其用途
WO2021057866A1 (zh) * 2019-09-26 2021-04-01 苏州克睿基因生物科技有限公司 一种单域抗体及包含抗体结构的嵌合抗原受体
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CA3155246A1 (en) * 2019-10-21 2021-04-29 Sandro MATOSEVIC Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
CN114929747A (zh) * 2019-11-05 2022-08-19 詹森生物科技公司 多发性骨髓瘤的靶向bcma的car-t细胞疗法
BR112022010206A2 (pt) 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
WO2021105989A1 (en) * 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptor to carbohydrate antigens
WO2021118246A1 (en) * 2019-12-10 2021-06-17 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
AU2020404272A1 (en) * 2019-12-16 2022-06-23 Legend Biotech Ireland Limited Single domain antibodies and chimeric antigen receptors targeting BCMA and methods of use thereof
CN111171158B (zh) * 2020-01-17 2020-10-30 南京蓝盾生物科技有限公司 同时靶向bcma和cd38的嵌合抗原受体及其应用
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CN115397973A (zh) * 2020-01-30 2022-11-25 免疫生物公司 表达car的nk细胞消除bcma阳性恶性肿瘤
CN111196858B (zh) * 2020-02-05 2021-02-09 武汉科技大学 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
EP4105240A4 (en) * 2020-02-13 2024-05-29 Sichuan University Chimeric antigen receptor and use thereof
US20230183312A1 (en) * 2020-02-14 2023-06-15 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors with cd2 activation
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
CN115768899A (zh) * 2020-03-09 2023-03-07 詹森生物科技公司 用于定量重组载体核酸整合的组合物和方法
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP4132542A2 (en) 2020-04-10 2023-02-15 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
KR20230015921A (ko) 2020-04-28 2023-01-31 주노 쎄러퓨티크스 인코퍼레이티드 Ｂｃｍａ-지시된 ｔ 세포 요법 및 면역 조절 화합물의 조합
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
CN115777017A (zh) * 2020-05-06 2023-03-10 亘喜生物科技（上海）有限公司 用于t细胞工程改造的组合物及方法
CN111574629B (zh) * 2020-06-01 2021-07-20 宁夏医科大学 一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
CN111607565A (zh) * 2020-06-04 2020-09-01 河南大学 一种北平顶猴t细胞的体外扩增方法
EP4162269A1 (en) * 2020-06-08 2023-04-12 Janssen Biotech, Inc. Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
KR20230021699A (ko) 2020-06-08 2023-02-14 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
EP4168437A1 (en) 2020-06-22 2023-04-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
WO2021263227A2 (en) * 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
WO2022011531A1 (zh) * 2020-07-14 2022-01-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CA3189548A1 (en) * 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
WO2022012683A1 (en) * 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd19 binding molecules and uses thereof
CN116323948A (zh) * 2020-07-16 2023-06-23 南京传奇生物科技有限公司 Cd22结合分子及其用途
US20230257475A1 (en) * 2020-07-16 2023-08-17 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric antigen receptors and uses thereof
CN111848798B (zh) * 2020-07-27 2022-05-13 源道隆（苏州）医学科技有限公司 可结合bcma的纳米抗体及其应用
KR20230042090A (ko) * 2020-07-29 2023-03-27 내션얼 리서치 카운슬 오브 캐나다 항-cd22 단일 도메인 항체 및 치료학적 작제물
CN111909271B (zh) * 2020-08-12 2021-03-23 深圳市茵冠生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及其应用
CN116390946A (zh) 2020-08-13 2023-07-04 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向磷脂酰肌醇蛋白聚糖-1（gpc1）的含igg4铰链的嵌合抗原受体
WO2022037528A1 (zh) 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
JP2023537958A (ja) 2020-08-20 2023-09-06 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo production of CAR expressing cells
CN112062864A (zh) * 2020-09-18 2020-12-11 樊克兴 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
CN111925451B (zh) * 2020-10-12 2021-01-29 佑仁细胞工程(浙江)有限公司 一种靶向bcma的嵌合抗原受体(car)及其应用
CN112251412B (zh) * 2020-10-12 2023-03-28 汤朝阳 一种靶向bcma的嵌合抗原受体t细胞及其应用
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN112028996B (zh) * 2020-10-30 2021-01-22 南京北恒生物科技有限公司 靶向bcma的单域抗体及其用途
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022116086A1 (en) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
EP4272002A1 (en) 2020-12-04 2023-11-08 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022143611A1 (zh) * 2020-12-29 2022-07-07 宁波茂行生物医药科技有限公司 靶向bcma的单域抗体
EP4263590A1 (en) 2020-12-21 2023-10-25 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CN113087798B (zh) * 2020-12-31 2022-05-24 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
TW202302841A (zh) 2020-12-31 2023-01-16 美商薩那生物科技公司 用於調變ｃａｒ－ｔ活性之方法與組成物
US20220241328A1 (en) 2021-01-11 2022-08-04 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
CN114149505B (zh) * 2021-01-12 2022-11-04 北京门罗生物科技有限公司 治疗b细胞相关疾病的免疫细胞、制备方法及其应用
EP4284836A4 (en) * 2021-01-27 2025-01-01 H. Lee Moffitt Cancer Center & Research Institute, Inc. Bi-specific car t cells for b cell malignancies
CN112778427B (zh) * 2021-01-29 2022-03-15 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
EP4284918A1 (en) 2021-01-29 2023-12-06 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
EP4291227A2 (en) 2021-02-15 2023-12-20 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
WO2022183160A1 (en) * 2021-02-25 2022-09-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods for treating cd83-expressing cancer
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CN117924497A (zh) * 2021-03-22 2024-04-26 浙江纳米抗体技术中心有限公司 一种靶向bcma的纳米抗体及其应用
KR20230166090A (ko) * 2021-04-06 2023-12-06 테네오바이오, 인코포레이티드 항-cd19 항체 및 car-t 구조체
WO2022221844A2 (en) * 2021-04-13 2022-10-20 WUGEN, Inc. Improved chimeric antigen receptors and uses thereof
AU2022256638A1 (en) 2021-04-15 2023-11-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Multi-specific antibody targeting bcma
CA3214280A1 (en) 2021-04-16 2022-10-20 Julie Ann RYTLEWSKI T cell therapy in patients who have had prior stem cell transplant
CN117337303A (zh) * 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
CA3214683A1 (en) 2021-04-16 2022-10-20 Julie Ann RYTLEWSKI Combination therapies with bcma-directed t cell therapy
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022228579A1 (en) * 2021-04-30 2022-11-03 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting gpc3 and methods of use thereof
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
AU2022272021A1 (en) 2021-05-11 2023-11-30 Janssen Biotech, Inc. Methods of minimizing neurotoxicity associated with chimeric antigen receptor (car) t cell therapy
US20240245772A1 (en) * 2021-05-19 2024-07-25 Celledit Llc Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such
EP4340851A1 (en) 2021-05-19 2024-03-27 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
MX2023014017A (es) 2021-05-27 2023-12-11 Sana Biotechnology Inc Celulas hipoinmunogenas que comprenden proteina variante del antigeno leucocitario humano e (hla-e) o una proteina variante del antigeno leucocitario humano g (hla-g) modificados geneticamente.
CN117500831A (zh) 2021-06-09 2024-02-02 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
WO2023278811A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
US20240316198A1 (en) 2021-07-14 2024-09-26 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
CN113651893B (zh) * 2021-08-12 2023-08-01 上海生物制品研究所有限责任公司 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
AU2022326908A1 (en) * 2021-08-12 2024-03-28 Cellogen Therapeutics Pvt. Ltd. Chimeric antigen receptors (car) for b cell malignancies
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
US11359012B1 (en) 2021-08-27 2022-06-14 Nanjing Kaedi Biotherapeutics Ltd. Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof
CN117586404A (zh) * 2021-09-24 2024-02-23 四川大学 可特异性靶向人EpCAM抗原的纳米抗体及应用
AU2022354068A1 (en) * 2021-09-29 2024-04-18 Modex Therapeutics, Inc. Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CA3234046A1 (en) * 2021-10-07 2023-04-13 Mehdi Arbabi-Ghahroudi Anti-bcma single domain antibodies and therapeutic constructs
EP4419117A1 (en) 2021-10-22 2024-08-28 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CN114015674B (zh) 2021-11-02 2024-08-30 辉大(上海)生物科技有限公司 一种CRISPR-Cas12i系统
JP2024540304A (ja) 2021-11-03 2024-10-31 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
KR20240117530A (ko) 2021-11-04 2024-08-01 얀센 바이오테크 인코포레이티드 다발성 골수종을 위한 bcma를 표적으로 하는 car-t 세포 요법
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20250017962A1 (en) 2021-11-09 2025-01-16 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof
CN115466331B (zh) * 2021-11-18 2023-05-30 合源生物科技(天津)有限公司 靶向bcma的嵌合抗原受体及其应用
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114195898B (zh) * 2021-12-13 2022-10-28 南京凯地医疗技术有限公司 人源化抗cd33的单域抗体及其构建体制备方法和应用
WO2023109257A1 (zh) * 2021-12-16 2023-06-22 浙江瑞加美生物科技有限公司 人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
EP4448549A2 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
US20240408192A1 (en) 2021-12-17 2024-12-12 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
EP4452285A1 (en) 2021-12-23 2024-10-30 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
EP4457248A2 (en) * 2021-12-29 2024-11-06 Rutgers, the State University of New Jersey Single-domain high affinity antibodies and methods of use thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN119013393A (zh) 2022-01-28 2024-11-22 朱诺治疗学股份有限公司 制造细胞组合物的方法
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
EP4473097A1 (en) 2022-02-02 2024-12-11 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
EP4479140A1 (en) 2022-02-15 2024-12-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
JP2025508720A (ja) 2022-02-17 2025-04-10 サナ バイオテクノロジー，インコーポレイテッド 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照
WO2023164695A2 (en) 2022-02-28 2023-08-31 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
JP2025513801A (ja) 2022-04-08 2025-04-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多部位受容体及びシグナル伝達複合体
CN114685664B (zh) * 2022-04-12 2023-10-20 内蒙古农业大学 抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023217067A1 (zh) * 2022-05-09 2023-11-16 上海先博生物科技有限公司 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
CN117279949B (zh) * 2022-05-27 2024-08-02 苏州易慕峰生物科技有限公司 包含cldn18.2单域抗体的嵌合抗原受体及其应用
EP4536710A1 (en) * 2022-06-13 2025-04-16 The Regents of the University of California Humanized antibodies to human integrin avb8
US12297285B2 (en) * 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN114805582B (zh) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 抗Trop2纳米抗体及其用途
AU2023299307A1 (en) 2022-06-30 2025-01-09 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024026455A2 (en) * 2022-07-29 2024-02-01 Shoreline Biosciences, Inc. Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages
EP4562134A1 (en) 2022-07-29 2025-06-04 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
EP4577575A1 (en) * 2022-08-25 2025-07-02 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
CN117384299B (zh) * 2022-11-01 2024-04-30 邦恩泰(山东)生物医药科技集团股份有限公司 靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
TW202430551A (zh) * 2022-11-02 2024-08-01 美商傳奇生物科技美國公司 多發性骨髓瘤之bcma靶向car-t細胞療法
CN120187854A (zh) * 2022-11-04 2025-06-20 丹娜-法伯癌症研究院 只有bcma vh的car
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024123836A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Immune-activating complexes
WO2024123835A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
CN117069844B (zh) * 2022-12-06 2024-02-09 成都赛恩吉诺生物科技有限公司 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
KR20240094169A (ko) * 2022-12-13 2024-06-25 진셀비티 주식회사 B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
CN115947853B (zh) * 2022-12-26 2024-06-28 河北森朗生物科技有限公司 靶向bcma的纳米抗体、嵌合抗原受体及其应用
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
WO2024175657A1 (en) 2023-02-22 2024-08-29 Astrazeneca Ab Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
CN117164712B (zh) * 2023-02-22 2024-05-24 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
WO2024206209A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Anti-cd38, anti-bcma, anti-gprc5d, and anti-fcrh5 antibodies and uses to treat various diseases such as cancer
AU2024244733A1 (en) 2023-03-31 2025-07-24 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
CN116640229B (zh) * 2023-04-10 2024-01-30 中国人民解放军总医院第五医学中心 一种低pH靶向性CAR-T细胞的构建及应用
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
FR3147946A1 (fr) * 2023-04-19 2024-10-25 Legend Biotech Usa Inc. Thérapie par cellule CAR-T ciblée par BCMA de Myélome Multiple
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN119486745A (zh) * 2023-05-24 2025-02-18 茂行制药(苏州)有限公司 用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN116655805B (zh) * 2023-05-31 2024-03-08 四川大学华西医院 一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116789859B (zh) * 2023-06-29 2024-02-23 徐州医科大学 一种用于评价bcma靶向car-t细胞药效的靶细胞及其应用
CN116949099B (zh) * 2023-07-12 2024-04-02 山东大学第二医院 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025029930A1 (en) 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
GR1010884B (el) * 2023-08-30 2025-02-19 Janssen Biotech, Inc., Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
CN117024594B (zh) * 2023-09-21 2025-02-28 武汉波睿达生物科技有限公司 一种抗cd20的纳米抗体及其应用
WO2025067472A1 (en) * 2023-09-27 2025-04-03 Nanjing Legend Biotech Co., Ltd. Methods of culturing gamma delta t cells
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076341A1 (en) 2023-10-05 2025-04-10 Janssen Biotech, Inc. Improved methods in lentiviral manufacturing for production of car-t cell drug products
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
WO2025096878A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics, Inc. Rna for in vivo transfection with increased expression
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
GB202317065D0 (en) 2023-11-07 2023-12-20 Coding Bio Ltd BCMA binding molecules
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025129201A1 (en) 2023-12-15 2025-06-19 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
US20250230470A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
CN117866903B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 单域抗体修饰的干细胞及其在疾病治疗中用途
CN117866904B (zh) * 2024-03-12 2024-06-07 北京贝来药业有限公司 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP2003524387A (ja) 1998-12-01 2003-08-19 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
WO2000061739A1 (en) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
JP5133494B2 (ja) 2001-08-10 2013-01-30 アバディーン ユニバーシティ 抗原結合ドメイン
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
JP2005516958A (ja) * 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
RS51318B (sr) 2002-12-16 2010-12-31 Genentech Inc. Varijante imunoglobulina i njihova upotreba
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
MX337587B (es) 2003-11-05 2016-03-11 Glycart Biotechnology Ag Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas.
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
DK1737891T3 (da) 2004-04-13 2013-03-25 Hoffmann La Roche Anti-p-selectin-antistoffer
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
SG188080A1 (en) 2004-07-22 2013-03-28 Univ Erasmus Medical Ct Binding molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1991580A2 (en) 2006-01-25 2008-11-19 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
SI2170389T1 (sl) * 2007-06-12 2015-03-31 Ac Immune S.A. Humanizirana protitelesa proti amiloidu beta
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
PT2509409T (pt) 2009-12-10 2016-09-29 Regeneron Pharma Ratinhos que produzem anticorpos de cadeia pesada
LT2580243T (lt) * 2010-06-09 2020-01-27 Genmab A/S Antikūnai prieš žmogaus cd38
EP2601218A4 (en) 2010-08-03 2015-02-18 Abbvie Inc VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
CN103987836B (zh) 2011-10-17 2018-04-10 麻省理工学院 细胞内传递
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US9783591B2 (en) * 2012-02-22 2017-10-10 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
NZ700362A (en) 2012-04-11 2016-09-30 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
US9765156B2 (en) * 2012-07-13 2017-09-19 The Trustees Of The University Of Pennsylvania Enhancing activity of CAR T cells by co-introducing a bispecific antibody
US9365641B2 (en) * 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2953972B1 (en) * 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP2981607B1 (en) * 2013-04-03 2020-08-19 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN103421115B (zh) 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
EP3119423B1 (en) * 2014-03-15 2022-12-14 Novartis AG Treatment of cancer using chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
NZ726989A (en) 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
EA038958B1 (ru) * 2014-08-04 2021-11-15 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
HK1245801B (en) * 2014-12-12 2020-05-15 2Seventy Bio, Inc. Bcma chimeric antigen receptors
AU2016297524B2 (en) 2015-07-20 2022-03-17 Angiocrine Bioscience, Inc. Engineered endothelial cells expressing an ets transcription factor
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh) 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
CN108395481B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
EP3612275A1 (en) 2017-04-19 2020-02-26 Allogene Therapeutics, Inc. Improved t cell compositions and methods
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN109306014B (zh) 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
JP7416695B2 (ja) 2017-12-29 2024-01-17 メモリアル スローン－ケタリング キャンサー センター 増強されたキメラ抗原受容体およびその使用
US20210023170A1 (en) 2018-02-12 2021-01-28 University Of Florida Research Foundation, Incorporated Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
MX2022002325A (es) 2019-08-28 2022-06-02 Nanjing Legend Biotech Co Ltd Linfocitos t que contienen nef y metodos para producirlos.
CA3152237A1 (en) 2019-08-30 2021-03-04 Janssen Biotech, Inc. B-cell maturation complex car t construct and primers
AU2020404272A1 (en) 2019-12-16 2022-06-23 Legend Biotech Ireland Limited Single domain antibodies and chimeric antigen receptors targeting BCMA and methods of use thereof
CN115768899A (zh) 2020-03-09 2023-03-07 詹森生物科技公司 用于定量重组载体核酸整合的组合物和方法
JP2023522400A (ja) 2020-04-24 2023-05-30 ヤンセン バイオテツク，インコーポレーテツド 手書きにおける変化を記述するための神経性毒性評価方法及びシステム
EP4162269A1 (en) 2020-06-08 2023-04-12 Janssen Biotech, Inc. Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells

Also Published As

Publication number Publication date
AU2016305075A1 (en) 2018-03-08
CR20210042A (es) 2021-02-26
US10934363B2 (en) 2021-03-02
CL2018000378A1 (es) 2018-08-17
PT4063397T (pt) 2024-07-29
CN113185615A (zh) 2021-07-30
FI3896091T3 (fi) 2023-12-04
US20210163615A1 (en) 2021-06-03
US20180230225A1 (en) 2018-08-16
JP2018525033A (ja) 2018-09-06
US20210261675A1 (en) 2021-08-26
HUS2400044I1 (hu) 2025-01-28
CA3019453C (en) 2023-04-04
CN113185616A (zh) 2021-07-30
EA201990208A1 (ru) 2019-07-31
AU2021200453B2 (en) 2023-03-30
CR20210225A (es) 2021-06-24
NZ750366A (en) 2022-10-28
KR20250107971A (ko) 2025-07-14
PL4063397T3 (pl) 2024-11-18
HRP20231542T1 (hr) 2024-03-15
ES2966992T3 (es) 2024-04-25
IL257297B (en) 2022-08-01
EP3896091A1 (en) 2021-10-20
CN105384825B (zh) 2018-06-01
CL2021001706A1 (es) 2022-01-28
CR20180153A (es) 2018-08-09
EP4063397A1 (en) 2022-09-28
UA126441C2 (uk) 2022-10-05
DK4063397T3 (da) 2024-07-22
PH12018500295B1 (en) 2023-08-11
NL301301I2 (nl) 2025-04-09
JP6851461B2 (ja) 2021-03-31
US12351638B2 (en) 2025-07-08
MY192392A (en) 2022-08-18
CL2019000326A1 (es) 2019-10-04
SMT202400311T1 (it) 2024-11-15
JP2019527557A (ja) 2019-10-03
LT3896091T (lt) 2023-12-27
CN109153731B (zh) 2021-04-02
AU2021200453C1 (en) 2023-11-16
FIC20240042I1 (fi) 2024-12-11
KR20180035918A (ko) 2018-04-06
MX2024010240A (es) 2024-09-11
AU2020200151B2 (en) 2022-03-17
US20200078399A1 (en) 2020-03-12
CN113234173A (zh) 2021-08-10
NO2024054I1 (no) 2024-12-10
EP4282878A2 (en) 2023-11-29
EP3475307A1 (en) 2019-05-01
EP4424376A3 (en) 2024-12-04
WO2017025038A1 (en) 2017-02-16
CN113234173B (zh) 2022-03-11
EP4063397B1 (en) 2024-06-19
JP2022183283A (ja) 2022-12-08
JP2021094037A (ja) 2021-06-24
CA2994579A1 (en) 2017-02-16
AU2020200151A1 (en) 2020-01-30
EA201890302A1 (ru) 2018-10-31
US11186647B2 (en) 2021-11-30
MX2018001739A (es) 2018-08-15
JP2021087455A (ja) 2021-06-10
DK3896091T3 (da) 2023-12-11
ZA201800703B (en) 2018-12-19
JP6859347B2 (ja) 2021-04-14
PH12018500295A1 (en) 2021-05-10
HUE064534T2 (hu) 2024-03-28
FR24C1050I1 (fr) 2025-01-17
KR102512934B1 (ko) 2023-03-23
KR20190065999A (ko) 2019-06-12
NZ778787A (en) 2025-05-02
SI3896091T1 (sl) 2024-03-29
US20220127371A1 (en) 2022-04-28
JP7696731B2 (ja) 2025-06-23
DK3896091T5 (da) 2024-08-05
EP4424376A2 (en) 2024-09-04
CA3019453A1 (en) 2018-02-15
CN109311999A (zh) 2019-02-05
IL294683A (en) 2022-09-01
JP2025028239A (ja) 2025-02-28
MX2019001294A (es) 2019-04-25
AU2016305075B2 (en) 2019-10-10
AU2020200151C1 (en) 2022-09-08
EP4282878A3 (en) 2024-03-06
CN113185616B (zh) 2024-03-01
BR112019002687A2 (pt) 2019-05-14
US20240409654A1 (en) 2024-12-12
RS64925B1 (sr) 2023-12-29
MX2024010239A (es) 2024-09-06
CL2021001686A1 (es) 2022-01-28
AU2022204180A1 (en) 2022-07-07
PH12019500193A1 (en) 2019-07-29
KR20240014108A (ko) 2024-01-31
BR112018002844A2 (pt) 2019-04-30
JP7168173B2 (ja) 2022-11-09
CN117756941A (zh) 2024-03-26
KR20240017408A (ko) 2024-02-07
CN109153731A (zh) 2019-01-04
RS65866B1 (sr) 2024-09-30
AU2017311089B2 (en) 2020-11-19
CO2018001405A2 (es) 2018-11-22
EP4282877A2 (en) 2023-11-29
CN113234174B (zh) 2024-01-09
JP2023024810A (ja) 2023-02-16
IL264607A (en) 2019-02-28
KR20230052294A (ko) 2023-04-19
MX2022015823A (es) 2023-01-24
MY188362A (en) 2021-12-03
CN118085090A (zh) 2024-05-28
PT3896091T (pt) 2023-11-29
EP3475307A4 (en) 2020-08-19
US11535677B2 (en) 2022-12-27
SA518390904B1 (ar) 2023-02-22
CR20190050A (es) 2019-06-11
PL3896091T3 (pl) 2024-04-29
HRP20241057T1 (hr) 2024-11-08
JP2024032975A (ja) 2024-03-12
KR20240173368A (ko) 2024-12-11
SI4063397T1 (sl) 2024-10-30
WO2018028647A1 (en) 2018-02-15
ZA201807836B (en) 2019-08-28
CA2994579C (en) 2023-07-11
CA3189388A1 (en) 2018-02-15
CN113234174A (zh) 2021-08-10
SG11201900635QA (en) 2019-02-27
CN105384825A (zh) 2016-03-09
LT4063397T (lt) 2024-09-25
HUE067869T2 (hu) 2024-11-28
IL257297A (en) 2018-03-29
AU2017311089A1 (en) 2019-02-21
ES2984851T3 (es) 2024-10-31
EP3334765A1 (en) 2018-06-20
EP3334765A4 (en) 2019-05-08
EP4282877A3 (en) 2024-02-21
EP3896091B1 (en) 2023-09-27
FI4063397T3 (fi) 2024-08-09
SMT202300425T1 (it) 2024-01-10
UA125818C2 (uk) 2022-06-15
SA519401072B1 (ar) 2024-02-01
CO2019000946A2 (es) 2019-02-08
AU2021200453A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
HUS2400044I1 (hu) Egydoménes antitesteken alapuló kiméra antigén-receptorok és eljárások alkalmazásukra
IL263626A (en) Chimeric antigen receptors and methods of use
IL265800A (en) Anti-lag-3 antibodies and methods of using them
IL266918A (en) Anti-ctla-4 antibodies and methods of using them
IL255336A0 (en) Chimeric antigen receptors and methods of using them
ZA201705720B (en) Anti-dll3 chimeric antigen receptors and methods of use
SG11201808411RA (en) Chimeric antigen and t cell receptors and methods of use
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
ZA201608305B (en) Monoclonal antibodies against her2 epitope and methods of use thereof
IL302660B1 (en) Chimeric antigen receptors and methods of using them
ZA201605655B (en) Chimeric antigen receptors and methods of making
HK1259251A1 (zh) 人源化抗c1s抗體及其使用方法
IL265957A (en) Anti-c1s antibodies and methods of using them
ZA201703471B (en) Anti-cldn chimeric antigen receptors and methods of use
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
HK40115252A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
HK1256354A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
AU2016222891A1 (en) Anti-DLL3 chimeric antigen receptors and methods of use